Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 3/20 | 0.36 |
| ▸ | SDCBP | O00560 | 3/20 | 0.35 |
| ▸ | SDC2 | P34741 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | BRS3 | P32247 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21117698 | 0.71 | ADAM17 (0.35) | — | |
| SCHEMBL120182 | 0.71 | ALOX15 (0.57) | ALOX15MAPTSMN1; SMN2KDM4ETHRB | |
| SCHEMBL16478074 | 0.66 | KCNH2 (0.38) | SDCBPSDC2 | |
| SCHEMBL9252869 | 0.66 | ADAM17 (0.45) | THRBMEN1KMT2A | |
| SCHEMBL122427 | 0.65 | KMT2A (0.57) | ALOX15SMN1; SMN2KDM4ETHRBMEN1 | |
| SCHEMBL25597830 | 0.64 | DRD2 (0.36) | — | |
| SCHEMBL22021891 | 0.63 | — | — | |
| SCHEMBL23424754 | 0.63 | KMT2A (0.46) | ALOX15MAPTSMN1; SMN2KDM4ETHRB | |
| SCHEMBL21696867 | 0.63 | KMT2A (0.53) | ALOX15SMN1; SMN2KDM4ETHRBMEN1 | |
| SCHEMBL21424557 | 0.62 | ALOX15 (0.46) | ALOX15MAPTSMN1; SMN2KDM4ETHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174531-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174531-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | ALOX15 881/4885MAPT 4475/4885SMN1; SMN2 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.